|Articles|September 1, 2001

Depression and Generalized Anxiety Disorder: Managed Care Considerations
Volume 7
Issue 11 Suppl

Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

Author(s)Philip T. Ninan, MD

Download PDF: Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

Articles in this issue

about 25 years ago

Article

Participating Faculty

about 25 years ago

Article

Introduction

about 25 years ago

Article

Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

about 25 years ago

Article

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

about 25 years ago

Article

The Pharmacoeconomics of Venlafaxine in Depression

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

Midsized Biotechs Strike MFN Drug Pricing Deals

Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis

Medicare Part D’s GLP-1 Dilemma: Adam Colborn, JD

FFRCT Helps Cut Unnecessary Heart Angiograms by 44%